Outcomes of Simultaneous Heart-Kidney Transplant With a Positive Crossmatch in the United States
Journal of Surgical Research · 2026-09 · 325 · 201-210
DOI: 10.1016/j.jss.2026.05.035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Research, 2026-09. Verfasst von Avery Wilson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Westchester Medical Center, Department of Surgery, Valhalla, New York; Massachusetts General Hospital, Department of Surgery, Center for Transplantat…. Hauptthemen laut MEDLINE: Kidney Transplantation, Heart Transplantation, Graft Rejection, Histocompatibility Testing. Die Arbeit nennt 43 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION The number of simultaneous heart-kidney transplants (SHKTs) being performed in the United States is steadily increasing. The aim of this study was to assess the association of a positive crossmatch (+XM) with outcomes in SHKT. MATERIALS AND METHODS We analyzed data from the United Network for Organ Sharing database among adult SHKT recipients between January 2014 and December 2023 and compared the outcomes between two cohorts: +XM and negative crossmatch (-XM). Primary outcomes were patient survival at 1-y and heart and kidney allograft survivals at 1-y posttransplant. Secondary outcomes were rates of allograft rejection and kidney delayed graft function. RESULTS One-year patient survival (+XM 88.5% versus -XM 89%, P = 0.83), heart graft survival (+XM 88.9 versus -XM 88.5%, P = 0.88) and kidney graft survival (+XM 84.6% versus -XM 85.1%, P = 0.67) were comparable between the two groups. +XM SHKT recipients had significantly higher rates of rejection in both heart (17% versus 8.1%, P < 0.001) and kidney allografts (8.3% versus 3.9%, P < 0.01) prior to initial discharge and for only kidney allograft at 1-y (5.8% versus 2.2%, P < 0.05) post-SHKT. On multivariable analysis, +XM was not associated with patient mortality, heart allograft failure, or kidney allograft failure. In SHKT candidates with +XM, survival was better with SHKT versus heart transplant alone (88.8% versus 70.4%, P < 0.05) CONCLUSIONS: Despite higher rates of rejection in heart and kidney allografts, +XM SHKT has comparable patient and graft outcomes versus -XM. In selected sensitized patients with concomitant heart and kidney disease, a +XM alone should not be a contraindication for SHKT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Westchester Medical Center, Department of Surgery, Valhalla, New York; Massachusetts General Hospital, Department of Surgery, Center for Transplantation Sciences, Boston, Massachusetts.
- Hartford Hospital, Division of Cardiothoracic Surgery, Hartford, Connecticut.
- Westchester Medical Center, Department of Surgery, Valhalla, New York.
- Westchester Medical Center, Department of Surgery, Valhalla, New York; Westchester Medical Center, Department of Medicine, Valhalla, New York.
- Westchester Medical Center, Department of Surgery, Valhalla, New York. Electronic address: Kenji.Okumura@wmchealth.org.
Zitieren
APA
Wilson, A., Ohira, S., Misawa, R., Dhand, A., & Okumura, K. (2026). Outcomes of Simultaneous Heart-Kidney Transplant With a Positive Crossmatch in the United States. Journal of Surgical Research, 325, 201-210. https://doi.org/10.1016/j.jss.2026.05.035
Vancouver
Wilson A, Ohira S, Misawa R, Dhand A, Okumura K. Outcomes of Simultaneous Heart-Kidney Transplant With a Positive Crossmatch in the United States. Journal of Surgical Research. 2026;325:201-210. doi:10.1016/j.jss.2026.05.035
BibTeX
@article{Wilson2026,
author = {Wilson, Avery and Ohira, Suguru and Misawa, Ryosuke and Dhand, Abhay and Okumura, Kenji},
title = {Outcomes of Simultaneous Heart-Kidney Transplant With a Positive Crossmatch in the United States},
journal = {Journal of Surgical Research},
year = {2026},
volume = {325},
pages = {201--210},
doi = {10.1016/j.jss.2026.05.035}
}
EUVIMED